Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.

SOUL is a large randomized, double-blind, placebo-controlled cardiovascular outcomes trial of oral semaglutide 14 mg daily versus placebo in 9650 people with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease.